Effects of constant infusion with insulin-like growth factor-I (IGF-I) to immature female rats on body weight gain, tissue growth, and sexual function

Endocrine ◽  
1997 ◽  
Vol 6 (1) ◽  
pp. 11-19 ◽  
Author(s):  
Nadine M. Gruaz ◽  
Violaine d'Allèves ◽  
Yves Charnay ◽  
Anna Skotther ◽  
Sven Ekvärn ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Growth Factor ◽  
Body Weight Gain ◽  
Tissue Growth ◽  
Female Rats ◽  
Constant Infusion ◽  
Immature Female ◽  
Factor I ◽  
Igf I

Inhibition of neonatal rat growth and circulating concentrations of insulin-like growth factor-I using an antiserum to rat growth hormone

1989 ◽  
Vol 122 (1) ◽  
pp. 79-86 ◽  
Author(s):  
D. J. Flint ◽  
M. J. Gardner
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Growth Factor ◽  
Body Weight Gain ◽  
Neonatal Rat ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I ◽  
Rat Growth ◽  
Growth Factor I

ABSTRACT Treatment of rats for 24 h on day 2, 10 or 20 of age with a specific antiserum to rGH (anti-(rGH)), GH, bromocriptine (CB-154) or prolactin failed to influence body weight gain or serum concentrations of insulin-like growth factor-I (IGF-I). On day 28 of age, however, anti-(rGH) completely inhibited body weight gain and markedly reduced circulating IGF-I concentrations, effects which were completely prevented by exogenous ovine GH (oGH). When administered to control rats on day 28 oGH caused supranormal weight gain and serum IGF-I concentrations. These results suggested that GH does not play a significant role in growth or regulation of serum IGF-I until after day 20 of age. By contrast, when anti-(rGH) was given for 4 consecutive days beginning on day 2 of life, body weight gain was reduced within 48 h and remained so until at least 28 days of age. Tail length was also significantly reduced. The effect was due to inhibition of GH effects since serum GH concentrations were low and exogenous GH prevented the effect. Inhibition of growth during the first 14 days of life occurred in the absence of any effect on serum IGF-I although by 21 days of age serum IGF-I was considerably lower than in control rats. The prolonged reduction in growth after treatment has stopped appeared to be due to a cytotoxic effect on the pituitary gland since pituitary weight and GH but not prolactin content were significantly decreased. The data are consistent with the hypothesis that in the neonate GH may be processed in serum so that a proportion of it is not recognized by an antiserum to pituitary GH. It would appear that inhibition of GH secretion reduces growth rate by at least 30–40% up to 14 days of age, 50% by 21 days of age and completely by 28 days. Effects of GH on growth could not be fully explained by regulation of serum IGF-I concentrations. Journal of Endocrinology (1989) 122, 79–86

Long-term reductions in GH, insulin-like growth factor-I and body weight gain in rats treated neonatally with antibodies to rat GH

1990 ◽  
Vol 124 (3) ◽  
pp. 381-386 ◽  
Author(s):  
M. J. Gardner ◽  
D. J. Flint
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Growth Factor ◽  
Body Weight Gain ◽  
Female Rats ◽  
Serum Prolactin ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Growth Factor I

ABSTRACT Treatment of neonatal rats on days 2–5 with antibodies against rat GH (rGH) markedly reduced body weight gain and serum concentrations of insulin-like growth factor-I for 6–8 weeks in both females and males, after which weight gain normalized without evidence of catch-up growth. There were no significant effects on serum prolactin, tri-iodothyronine or corticosterone. Testis and ovarian weights were reduced, although only in proportion to body size. In females, but not males, the treated rats, though lighter, had increased fat deposition in the parametrial depot. Pituitary weight was considerably reduced over 100 days later, as was the pituitary content of GH, but not prolactin. The response to GH-releasing factor of both male and female rats was also greatly reduced at this time. Taken together with the fact that these rGH antibodies can bind directly to somatotrophs, we propose that the long-term effects of the antibodies are induced by specific somatotroph destruction. Journal of Endocrinology (1990) 124, 381–386

Effects of insulin-like growth factor-I peptides in rats with acute renal failure

1994 ◽  
Vol 140 (1) ◽  
pp. 23-32 ◽  
Author(s):  
A A Martin ◽  
C M Gillespie ◽  
L Moore ◽  
F J Ballard ◽  
L C Read
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Body Weight ◽  
Acute Renal Failure ◽  
Weight Gain ◽  
Growth Factor ◽  
Body Weight Gain ◽  
Factor I ◽  
Renal Ischaemia ◽  
Igf I

Abstract The effect of insulin-like growth factor-I (IGF-I) administration on body weight gain and the rate of recovery of renal function was investigated in rats following an acute episode of renal ischaemia. Since the des(1–3)IGF-I and LR3IGF-I variant forms of IGF-I have been shown to be more potent than IGF-I, their effects were also examined. Acute renal failure was produced in male Sprague–Dawley rats by clamping both renal arteries for 45 min. Treatment was commenced at the time of renal artery occlusion with vehicle (0·1 mol acetic acid/l; control group), IGF-I (2·0 mg/kg per day), des(1–3)IGF-I (2·0 mg/kg per day) or LR3IGF-I (1·5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages. Glomerular filtration rate (GFR) was estimated by the use of 51Cr-EDTA continuously infused i.p. via osmotic pump. Following the episode of renal ischaemia, body weight gain and nitrogen retention were significantly improved in all three peptide-treated groups, and serum urea concentrations were reduced in the groups treated with IGF-I and des(1–3)IGF-I. However, there was no evidence of the variants having any increased potency over the growth effects of IGF-I itself. GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent. A closer examination of the acute effects of LR3IGF-I on renal function was undertaken by measuring GFR for 3 days before and 3 days after renal ischaemia in two groups of rats, treated for the latter 3 days with either vehicle (controls) or LR3IGF-I (1·5 mg/kg per day). LR3IGF-I treatment following renal ischaemia resulted in a significantly greater fall in GFR than in controls, urinary osmolality was also significantly reduced, and fractional excretion of sodium was increased. In addition, there was histological evidence of a greater degree of tubular epithelial calcification in the kidneys of the rats treated with LR3IGF-I. This study showed that administration of IGF peptides at doses sufficient to cause significant improvement in anabolic status did not improve renal function in rats following an acute episode of renal ischaemia. Indeed the LR3IGF-I variant of IGF-I had a deleterious effect on renal function in the early stage of the recovery period. Journal of Endocrinology (1994) 140, 23–32

Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation

2007 ◽  
Vol 292 (6) ◽  
pp. E1656-E1665 ◽  
Author(s):  
Miriam Granado ◽  
Ana I Martín ◽  
Mª Ángeles Villanúa ◽  
Asunción López-Calderón
Keyword(s):  
Gene Expression ◽  
Body Weight ◽  
Weight Gain ◽  
Muscle Wasting ◽  
Body Weight Gain ◽  
Chronic Arthritis ◽  
Factor I ◽  
Tnf Α ◽  
Igf I ◽  
Cox 2

Chronic arthritis induces cachexia associated with an inhibition of the growth hormone (GH)-insulin-like growth factor-I (IGF-I) system and an activation of the E3 ubiquitin-ligating enzymes muscle atrophy F-box (MAFbx) and muscle Ring finger 1 (MuRF1) in the skeletal muscle. The aim of this work was to study the role of cyclooxygenase (COX)-2 in chronic arthritis-induced cachexia. Arthritis was induced in rats by Freund's adjuvant injection, and the effects of two COX inhibitors (indomethacin, a nonspecific inhibitor, and meloxicam, a selective COX-2 inhibitor on pituitary GH and on liver and serum IGF-I levels) were tested. Arthritis decreased body weight gain and GH and liver IGF-I gene expression. In the arthritic rats, both inhibitors, indomethacin and meloxicam, prevented the inhibitory effect of arthritis on body weight gain. Indomethacin and meloxicam administration to arthritic rats increased pituitary GH and liver IGF-I mRNA as well as serum levels of IGF-I. These data suggest that induction of COX-2 during chronic inflammation is involved in the inhibition of the GH-IGF-I axis and in the body weight loss. In the gastrocnemius muscle, arthritis increased the gene expression of tumor necrosis factor (TNF)-α, the E3 ubiquitin-ligating enzymes MAFbx and MuRF1, as well as of IGF-I and IGF-binding protein-5 (IGFBP-5). Inhibition of COX-2 by meloxicam administration increased gastrocnemius weight and decreased MAFbx, MuRF1, TNF-α, and IGFBP-5 gene expression. In summary, our data indicate that chronic arthritis-induced cachexia and muscle wasting are mediated by the COX-2 pathway resulting in a decreased GH-IGF-I secretion and increased expression of MAFbx and MuRF1 mRNA.

Reduced serum concentrations of insulin-like growth factor-I (IGF-I) in protein-restricted growing rats are accompanied by reduced IGF-I mRNA levels in liver and skeletal muscle

1991 ◽  
Vol 130 (2) ◽  
pp. 305-312 ◽  
Author(s):  
M. J. VandeHaar ◽  
B. M. Moats-Staats ◽  
M. L. Davenport ◽  
J. L. Walker ◽  
J.-M. Ketelslegers ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Protein Restriction ◽  
Mrna Abundance ◽  
Factor I ◽  
Growing Rats ◽  
Low Protein ◽  
Igf I

ABSTRACT The serum concentration of insulin-like growth factor-I (IGF-I) is reduced in growing rats fed a low-protein diet, and this decrease is age-dependent, being more pronounced in younger animals. To determine whether this decrease in serum IGF-I is related to a decrease in IGF-I mRNA, growing female rats were given free access to either a 15% protein-sufficient or a 5% protein-deficient diet for 1 week. Protein restriction in 4-week-old rats decreased body weight gain by 44% (P < 0·001) compared with 4-week controls), serum IGF-I concentration by 67% (P < 0·001) and liver IGF-I mRNA abundance by 51% (P < 0·001). During week 6, protein restriction for 1 week resulted in a 20% increase in food intake with no change in weight gain, a 38% reduction in serum IGF-I (P < 0·001 compared with 6-week controls) and a 39% decrease in liver IGF-I mRNA (P < 0·001). The serum IGF-I concentration was highly correlated (r = 0·80; P < 0·001) with the hepatic IGF-I mRNA concentration. Skeletal muscle IGF-I mRNA abundance was also decreased significantly by protein restriction (37% at week 4, P<0·001, and 24% at week 6, P < 0·01) and was closely correlated (r = 0·71; P < 0·001) with body weight gain. Liver GH-binding protein and GH receptor mRNA abundance were reduced by 1 week of protein deprivation at week 6 but not at week 4. We conclude that the reduced serum IGF-I of young rats fed a low-protein diet is due, in part, to reduced liver IGF-I mRNA, and that these changes are not dependent on GH binding. Decreased skeletal muscle IGF-I mRNA during protein restriction is consistent with an autocrine/paracrine action of IGF-I in muscle. Journal of Endocrinology (1991) 130, 305–312

Effects of an aromatase inhibitor on testosterone-induced inhibition of thymus growth in immature female rats

1988 ◽  
Vol 119 (1) ◽  
pp. 65-67 ◽  
Author(s):  
B. D. Greenstein ◽  
B. J. Mander ◽  
F. T. A. Fitzpatrick
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Aromatase Inhibitor ◽  
Inhibitory Action ◽  
Body Weight Gain ◽  
Female Rats ◽  
Silicone Elastomer ◽  
Immature Female

ABSTRACT The hypothesis was tested that the inhibitory action of testosterone on thymus growth is mediated by its metabolism to oestradiol. Immature female rats were given s.c. implants of silicone elastomer tubing containing 5 or 20 mg testosterone alone, or together with 25 or 50 mg of an aromatase inhibitor 1,4,6-androstatriene-3,17-dione (ATD). Some rats received implants containing 5 mg oestradiol or 5 mg dihydrotestosterone (DHT). After 14 days the thymus was removed and weighed. Body weight gain was similar in animals treated with empty implants, or 5 mg testosterone or DHT, or with ATD alone. The combination of testosterone and ATD significantly increased body weight gain, and oestradiol significantly decreased it. Thymus growth was inhibited by both doses of testosterone and by oestradiol, but not by DHT. ATD alone did not inhibit thymus growth, nor did the lower dose of ATD inhibit the action of testosterone. The higher dose of ATD did, however, significantly reduce the inhibitory action of testosterone on the thymus. The inhibitory action of testosterone on the growing thymus may be due, at least in part, to its conversion to oestradiol. J. Endocr. (1988) 119, 65–67

scholarly journals Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure

2012 ◽  
Vol 303 (5) ◽  
pp. G610-G622 ◽  
Author(s):  
Adam S. Brinkman ◽  
Sangita G. Murali ◽  
Stacy Hitt ◽  
Patrick M. Solverson ◽  
Jens J. Holst ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Growth Factor ◽  
Parenteral Nutrition ◽  
Rat Model ◽  
Bowel Resection ◽  
Body Weight Gain ◽  
Igf I ◽  
Glucagon Like Peptide ◽  
Enteral Nutrients

Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent, proglucagon-derived gut hormone that shows promise for the treatment of short bowel syndrome (SBS). Our objective was to investigate how combination GLP-2 + enteral nutrients (EN) affects intestinal adaption in a rat model that mimics severe human SBS and requires parenteral nutrition (PN). Male Sprague-Dawley rats were assigned to one of five groups and maintained with PN for 18 days: total parenteral nutrition (TPN) alone, TPN + GLP-2 (100 μg·kg−1·day−1), PN + EN + GLP-2(7 days), PN + EN + GLP-2(18 days), and a nonsurgical oral reference group. Animals underwent massive distal bowel resection followed by jejunocolic anastomosis and placement of jugular catheters. Starting on postoperative day 4, rats in the EN groups were allowed ad libitum access to EN. Groups provided PN + EN + GLP-2 had their rate of PN reduced by 0.25 ml/day starting on postoperative day 6. Groups provided PN + EN + GLP-2 demonstrated significantly greater body weight gain with similar energy intake and a safe 80% reduction in PN compared with TPN ± GLP-2. Groups provided PN + EN + GLP-2 for 7 or 18 days showed similar body weight gain, residual jejunal length, and digestive capacity. Groups provided PN + EN + GLP-2 showed increased jejunal GLP-2 receptor (GLP-2R), insulin-like growth factor-I (IGF-I), and IGF-binding protein-5 (IGFBP-5) expression. Treatment with TPN + GLP-2 demonstrated increased jejunal expression of epidermal growth factor. Cessation of GLP-2 after 7 days with continued EN sustained the majority of intestinal adaption and significantly increased expression of colonic proglucagon compared with PN + EN + GLP-2 for 18 days, and increased plasma GLP-2 concentrations compared with TPN alone. In summary, EN potentiate the intestinotrophic actions of GLP-2 by improving body weight gain allowing for a safe 80% reduction in PN with increased jejunal expression of GLP-2R, IGF-I, and IGFBP-5 following distal bowel resection in the rat.

Sign in / Sign up

Export Citation Format

Share Document